• Scaling Allo with Allogene Therapeutics' Dr. Zachary Roberts

  • Aug 29 2024
  • Length: 25 mins
  • Podcast

Scaling Allo with Allogene Therapeutics' Dr. Zachary Roberts

Listen for free

View show details

  • Summary

  • We love to hear from our listeners. Send us a message.

    Allogene Therapeutics' EVP of R&D and CMO, Dr. Zachary Roberts, penned an original article for Cell & Gene titled, The Path Forward for CLL is Allogeneic. In his article, Dr. Roberts explains that chronic lymphocytic leukemia (CLL) is the most common leukemia in the U.S. And that while CLL remains a disease that is managed, it is not one that is often cured. In this episode, Host Erin Harris follows up Roberts' article with in-depth questions around existing issues with current CAR T approaches, "auto versus allo," and why allogeneic is the path forward. They also discuss how and why allogeneic therapies are truly scalable.

    Subscribe to the podcast!
    Apple | Spotify | YouTube
    Show more Show less
Show more Show less
activate_Holiday_promo_in_buybox_DT_T2

What listeners say about Scaling Allo with Allogene Therapeutics' Dr. Zachary Roberts

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com reviews

Amazon reviews
No Reviews are Available